Vlatko Pejsa

Vlatko Pejsa

Auto-generated profile, based on publicly available information

Vlatko Pejsa

Division of Hematology, Department of Medicine University Hospital Dubrava Zagreb Croatia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
KPKeith W. Pratz
Keith W. Pratz
PPPanayiotis Panayiotidis
Panayiotis Panayiotidis
CRChristian Récher
Christian Récher
XWXudong Wei
Xudong Wei
BJBrian A Jonas
Brian A Jonas
Walter FiedlerWalter Fiedler
Walter Fiedler
Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.

1 February 2017 in Croatian Medical Journal
Verified
Journal Article
Open access
VPVlatko Pejša
Vlatko Pejša
ŽPŽeljko Prka
Željko Prka
MLMarko Lucijanic
Marko Lucijanic
ZMZdravko Mitrović
Zdravko Mitrović
MPMario Piršić
Mario Piršić
RKRajko Kušec
Rajko Kušec
To assess the benefit of rituximab with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) regimen as a first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL) presenting with unfavorable ...

13 November 2018 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
VPVlatko Pejsa
Vlatko Pejsa
MLMarko Lucijanic
Marko Lucijanic
ZJZeljko Jonjic
Zeljko Jonjic
ZPZeljko Prka
Zeljko Prka
GVGorana Vukorepa
Gorana Vukorepa

5 November 2018 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
MLMarko Lucijanic
Marko Lucijanic
ZPZeljko Prka
Zeljko Prka
OJOzren Jaksic
Ozren Jaksic
ZMZdravko Mitrovic
Zdravko Mitrovic
AVAnamarija Vrkljan
Anamarija Vrkljan
VPVlatko Pejsa
Vlatko Pejsa

16 December 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
VPVlatko Pejsa
Vlatko Pejsa
MLMarko Lucijanic
Marko Lucijanic
AVAnamarija Vrkljan Vuk
Anamarija Vrkljan Vuk
TSTajana Stoos-Veic
Tajana Stoos-Veic
OJOzren Jaksic
Ozren Jaksic
ZMZdravko Mitrovic
Zdravko Mitrovic
First obinutuzumab application is associated with infusion related reactions (IRRs) that may discourage further continuation of the drug. During our clinical practice we have observed that chronic lymphocytic leukemia (CLL) patients with autoimmune hemolytic anemia (AIHA) prolongedly receiving corticosteroids do not develop obinutuzumab IRRs. Therefore, we decided to apply prolonged corticosteroid premedication with methylprednisolone in dose 1–1.5 mg/kg for ≥7 days to all further obinutuzumab candidates. Here we present non-randomized comparison of 28 consecutive previously untreated CLL patients receiving prolonged corticosteroid premedication (15 patients) or standard premedication (13 patients) prior to the first obinutuzumab infusion. Prolonged corticosteroid premedication resulted in significant reduction of all-grade (20% vs 61.5%; p = .025) and grade III (0% vs 23.1%; p = .049) obinutuzumab IRRs. Prolonged corticosteroid premedication did not significantly affect occurrence of infective complications. Patients with CLL and AIHA receiving obinutuzumab showed continuous and stable increase in hemoglobin levels concomitantly with decrease in parameters of hemolysis.

1 June 2010
Verified
Journal Article
Closed access
TSTajana Stoos-Veic
Tajana Stoos-Veic
ALAna Livun
Ana Livun
RARadmila Ajduković
Radmila Ajduković
VPVlatko Pejsa
Vlatko Pejsa
OJOzren Jaksić
Ozren Jaksić
RKRajko Kusec
Rajko Kusec